1. Home
  2. MTEK vs BCDA Comparison

MTEK vs BCDA Comparison

Compare MTEK & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

N/A

Current Price

$1.52

Market Cap

12.6M

Sector

N/A

ML Signal

N/A

BCDA

BioCardia Inc.

N/A

Current Price

$1.30

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MTEK
BCDA
Founded
2008
N/A
Country
Israel
United States
Employees
N/A
17
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
12.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MTEK
BCDA
Price
$1.52
$1.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
1.4M
62.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$1.00
52 Week High
$4.27
$3.20

Technical Indicators

Market Signals
Indicator
MTEK
BCDA
Relative Strength Index (RSI) 43.06 52.21
Support Level $1.48 $1.26
Resistance Level $1.57 $1.39
Average True Range (ATR) 0.25 0.10
MACD -0.04 0.01
Stochastic Oscillator 1.53 59.42

Price Performance

Historical Comparison
MTEK
BCDA

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: